March 2024: Zanubrutinib (Brukinsa, BeiGene USA, Inc.) in combination with obinutuzumab has been granted accelerated approval by the Food and Drug Administration for the treatment of relapsed or refractory follicular lymphoma (FL)..
If you're reading this, you or maybe one of your loved ones is on a journey that no one ever plans to take—the path of facing cancer. We understand that this road is filled with uncertainties, fears, and moments when it feel..
Zitholele isayensi ngemuva kokwelashwa kwe-CAR T Cell eNdiya! Hlola ukuthi lokhu kwelashwa okuguquguqukayo kuwaguqula kanjani amaseli akho omzimba abe yizilwi zomdlavuza. Funda ibhulogi yethu manje ukuze ufunde kabanzi mayelana nalokhu kwelashwa okuyisimangaliso nokuthi kanjani ..
Wake wazibuza ukuthi ikhona yini indlela enamandla yokulwa nomdlavuza? Manje ake ucabange nje uma ngolunye usuku uthole umsebe wethemba ekulweni kwakho nomdlavuza, ukwelashwa okusebenzisa amandla amasosha omzimba wakho ukukhomba isifo somdlavuza.
Meyi 2023: Ezigulini ezikhulile ezinezinga eliphezulu le-B-cell lymphoma (HGBL), engacacisiwe ngenye indlela (NOS), noma ezisabalalisa i-B-cell lymphoma (DLBCL) enkulu ezingakaze zithole ukwelashwa futhi ezine-International Prognostic Inde.
SHANGHAI, CHINA, October 10, 2022 - JW Therapeutics (HKEX: 2126), an independent and innovative biotechnology company focusing on developing, manufacturing, and commercializing cell immunotherapy products, announced that the Na..
Feb 2023: The results of the trial demonstrated that a novel chimeric antigen receptor T-cell therapy elicited a response in adults with advanced large B-cell lymphoma who had relapsed following prior CAR-T. According to stati..
Feb 2023: Ukugunyazwa okusheshisiwe kunikezwa yi-FDA ku-pirtobrutinib (Jaypirca, Eli Lilly and Company) ye-refractory mantle cell lymphoma. E-BRUIN (NCT03740529), ilebula evulekile, ephakathi nendawo, yengalo eyodwa ye-pirtobr.
Feb 2023: Zanubrutinib (Brukinsa, BeiGene USA, Inc.) is approved by FDA for chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). SEQUOIA was used to assess effectiveness in CLL/SLL patients who had not recei..
Novemba 2022: Inhlanganisela ye-doxorubicin, i-vincristine, i-etoposide, i-prednisone, ne-cyclophosphamide ene-brentuximab vedotin (Adcetris, Seagen, Inc.) igunyazwe i-Food and Drug Administration ukuze isetshenziswe ezinganeni.